Borges, Andreia; Pereira, Filipa; Redondo, Patrícia; … - In: Health Economics Review 11 (2021) 1, pp. 1-13
Background: Breast cancer (BC) is largely prevalent worldwide. HER2-positive BC account for roughly 20-25% of all BC …-effectiveness of adding pertuzumab in neoadjuvant treatment (NeoT) for HER2-positive breast cancer (BC). Methods: Two retrospective … real-world consecutive cohorts of ≥18yo female patients diagnosed with HER2- positive BC treated with NeoT at the Breast …